LOXO-RAS-20001: A Phase 1a/1b Study of LY3537982 in Patients with KRAS G12C-Mutant Advanced Solid Tumors

The main purpose of this research study (during both monotherapy and combination therapy evaluation) includes the following: To determine whether LY3537982 is safe; To identify which dose level of LY3537982, by itself or in combination with other investigational agents, should be studied in future studies; To identify which of the dose levels used in this study is the highest tolerated dose or the dose that causes side effects that are too severe to continue treatment with LY3537982 by itself or in combination with other investigational agents; To evaluate how the body absorbs and processes different doses of LY3537982 by measuring the levels of LY3537982 in the blood at different times [this is called pharmacokinetic (PK) testing] by itself or in combination with other investigational agents; To determine how well your cancer responds to treatment with LY3537982 by itself or in combination with other investigational agents; To determine how long any benefits from treatment with LY3537982 by itself or in combination with other investigational agents last.